ArticleJournal of psychopharmacology (Oxford, England)2018
The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.
Article in Journal of psychopharmacology (Oxford, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05698095 (A Phase 1, First-in-human, Double-blind, Placebo-controlled, Randomized, Single- and Multiple-ascending-dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine), which is not on this map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1, First-in-human, Double-blind, Placebo-controlled, Randomized, Single- and Multiple-ascending-dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) Administered by Intramuscular Injection in Healthy Subjects
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 134 citations in OpenAlex.
- Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials.Frontiers in psychiatry · 2024Pooled it
- Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults.Scientific reports · 2025Trial
- Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-Journal of psychopharmacology (Oxford, England) · 2024Trial
- Moving beyond 5-HTPsychopharmacology · 2026Article
- Efficacy and Safety of Psychoactive Tryptamines in Addiction: A Systematic Review.Psychedelic medicine (New Rochelle, N.Y.) · 2026Article
- Neuropharmacology of halogenated DMT analogs: psychoplastogenic and antidepressant properties of 5-Br-DMT, a psychedelic derivative with low hallucinogenic potential.Molecular psychiatry · 2026Article
- Mindset over molecule: comparing self-transcendent and mystical experiences across recreational psilocybin, MDMA, and cannabis use.BMC psychology · 2026Article
- Flashbacks, Hallucinogen Persisting Perception Disorder (HPPD), and Reactivations Following the Use of Classic Psychedelics: Classification and Therapeutic Management.Current topics in behavioral neurosciences · 2026Review
- Mind the gap! Addressing unresolved aspects of abuse potential evaluation and scheduling of classic and novel psychedelic drugs.Journal of psychopharmacology (Oxford, England) · 2026Review
- Exploring the therapeutic potential of psychedelics: Fear extinction mechanisms and amygdala modulation.Psychedelics · 2025Article
- Serotonin 1A Receptors Modulate Serotonin 2A Receptor-Mediated Behavioral Effects of 5-Methoxy-ACS chemical neuroscience · 2024Article
- Epigenetic mechanisms of rapid-acting antidepressants.Translational psychiatry · 2024Review
- Novel Thermosensitive and Mucoadhesive Nasal Hydrogel Containing 5-MeO-DMT Optimized Using Box-Behnken Experimental Design.Polymers · 2024Article
- 5-MeO-DMT induces sleep-like LFP spectral signatures in the hippocampus and prefrontal cortex of awake rats.Scientific reports · 2024Article
- The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action.Addiction biology · 2024Review
- Effects of DMT on mental health outcomes in healthy volunteers.Scientific reports · 2024Article
- Effects of hallucinogenic drugs on the human heart.Frontiers in pharmacology · 2024Review
- Psychedelics: From Cave Art to 21st-Century Medicine for Addiction.European addiction research · 2024Review
- Mechanisms of integration in psychedelic-assisted therapy.Journal of military, veteran and family health · 2023Review
- 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
BACKGROUND/
aim5-Methoxy- N,N-dimethyltryptamine (5-MeO-DMT) is a psychoactive compound found in several plants and in high concentrations in Bufo alvarius toad venom. Synthetic, toad, and plant-sourced 5-MeO-DMT are used for spiritual and recreational purposes and may have psychotherapeutic effects. However, the use of 5-MeO-DMT is not well understood. Therefore, we examined patterns of use, motivations for consumption, subjective effects, and potential benefits and consequences associated with 5-MeO-DMT use.
methodsUsing internet-based advertisements, 515 respondents ( M
resultsMost respondents consumed 5-MeO-DMT infrequently (<once/year), for spiritual exploration, and had used less than four times in their lifetime. The majority (average of 90%) reported moderate-to-strong mystical-type experiences ( M
conclusionFindings suggest that 5-MeO-DMT is used infrequently, predominantly for spiritual exploration, has low potential for addiction, and might have psychotherapeutic effects. Future research should examine the safety and pharmacokinetics of 5-MeO-DMT administration in humans using rigorous experimental designs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.